Kinney Horn

Kinney Horn's Title

Kinney Horn holds the prestigious position of Chief Business Officer. In this role, he leverages his extensive expertise in life science finance, leadership, operations, and biopharmaceutical business development. As a chief business officer, Horn is responsible for driving strategic growth, overseeing critical business operations, and managing high-stakes financial transactions.

Kinney Horn's Experience at Olema Oncology

As the Chief Business Officer at Olema Oncology, Kinney Horn played a pivotal role in the company's financial and strategic milestones. His leadership was instrumental in the completion of an $85M Series C crossover financing round and the company's successful $240M IPO. These achievements underscore his adeptness at navigating complex financial landscapes and securing critical funding for biopharmaceutical ventures.

Kinney Horn's Career at Genentech

During his 16-year tenure at Genentech, Kinney Horn amassed a wealth of experience in transaction management and strategic sourcing. He led teams of up to 50 employees to identify pre-clinical and clinical stage opportunities, structure strategic alliances, and negotiate and close deals. His efforts were particularly impactful in the oncology sector, where he managed the annual strategic sourcing process for 13 research and development areas. Additionally, Horn worked closely with early-stage biotechnology companies through GenenFUND, Genentech's private equity fund.

Kinney Horn's International Experience

Kinney Horn's professional journey is marked by significant international experience, encompassing negotiations with companies in Europe and Asia. This global perspective has enriched his ability to navigate diverse regulatory environments and foster cross-border strategic alliances. His international expertise is a valuable asset in the increasingly globalized biopharmaceutical industry.

Kinney Horn's Education and Expertise

Kinney Horn's academic background is as diverse as it is impressive. He holds degrees in economics, international affairs, and biochemistry from Mary Washington College and Georgetown University. This multidisciplinary education equips him with a comprehensive understanding of both the scientific and economic facets of the biopharmaceutical industry, enabling him to bridge the gap between innovative research and strategic business development.